ThromboGenics' Founder Prof Desire Collen Retiring as Chairman

ThromboGenics' Founder Prof DesireThromboGenics' Founder Prof Desire Collen Retiring as Chairman PR Newswire LEUVEN, Belgium, December 6, 2013 Dr Staf Van Reet appointed as new Chairman of the Board ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that Prof Désiré Collen has decided to retire as Chairman and board member. Dr Staf Van Reet, currently a member of the ThromboGenics Board and a seasoned biopharma veteran, has been appointed Chairman of ThromboGenics. Prof Collen, Founder and Chairman of ThromboGenics, said: "As the founder and a key member of the ThromboGenics team for more than 20 years, I've decided it is time for me to take a step back and to stand down from my current role as ThromboGenics' Chairman. I believe that this is an appropriate time to hand over to my successor. "Recognizing a number of challenges, I believe that the Company has a ®clear strategy to optimize the US sales of JETREA and in the rest of the ®world via its partner Alcon. I remain confident that JETREA will find its way forward as part of a new standard of care for the treatment of symptomatic VMA/VMT, particularly for earlier stage patients." Prof Collen, a world renowned scientist, has played an instrumental role in ThromboGenics' development and subsequent success since he founded the Company in 1991.